152 related articles for article (PubMed ID: 25211704)
1. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.
Andreoli M; Persico M; Kumar A; Orteca N; Kumar V; Pepe A; Mahalingam S; Alegria AE; Petrella L; Sevciunaite L; Camperchioli A; Mariani M; Di Dato A; Novellino E; Scambia G; Malhotra SV; Ferlini C; Fattorusso C
J Med Chem; 2014 Oct; 57(19):7916-32. PubMed ID: 25211704
[TBL] [Abstract][Full Text] [Related]
2. GTP is an allosteric modulator of the interaction between the guanylate-binding protein 1 and the prosurvival kinase PIM1.
Persico M; Petrella L; Orteca N; Di Dato A; Mariani M; Andreoli M; De Donato M; Scambia G; Novellino E; Ferlini C; Fattorusso C
Eur J Med Chem; 2015 Feb; 91():132-44. PubMed ID: 25081641
[TBL] [Abstract][Full Text] [Related]
3. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
[TBL] [Abstract][Full Text] [Related]
4. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
[TBL] [Abstract][Full Text] [Related]
5. PIM1 controls GBP1 activity to limit self-damage and to guard against pathogen infection.
Fisch D; Pfleiderer MM; Anastasakou E; Mackie GM; Wendt F; Liu X; Clough B; Lara-Reyna S; Encheva V; Snijders AP; Bando H; Yamamoto M; Beggs AD; Mercer J; Shenoy AR; Wollscheid B; Maslowski KM; Galej WP; Frickel EM
Science; 2023 Oct; 382(6666):eadg2253. PubMed ID: 37797010
[TBL] [Abstract][Full Text] [Related]
6. Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors.
Olla S; Manetti F; Crespan E; Maga G; Angelucci A; Schenone S; Bologna M; Botta M
Bioorg Med Chem Lett; 2009 Mar; 19(5):1512-6. PubMed ID: 19179076
[TBL] [Abstract][Full Text] [Related]
7. Identification of quinones as novel PIM1 kinase inhibitors.
Schroeder RL; Goyal N; Bratton M; Townley I; Pham NA; Tram P; Stone T; Geathers J; Nguyen K; Sridhar J
Bioorg Med Chem Lett; 2016 Jul; 26(13):3187-3191. PubMed ID: 27173800
[TBL] [Abstract][Full Text] [Related]
8. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase.
Anjum F; Mohammad T; Almalki AA; Akhtar O; Abdullaev B; Hassan MI
OMICS; 2021 Sep; 25(9):580-590. PubMed ID: 34448628
[TBL] [Abstract][Full Text] [Related]
9. Insights from Pim1 structure for anti-cancer drug design.
Ogawa N; Yuki H; Tanaka A
Expert Opin Drug Discov; 2012 Dec; 7(12):1177-92. PubMed ID: 23004574
[TBL] [Abstract][Full Text] [Related]
10. 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase.
Aouidate A; Ghaleb A; Ghamali M; Ousaa A; Choukrad M; Sbai A; Bouachrine M; Lakhlifi T
Comput Biol Chem; 2018 Jun; 74():201-211. PubMed ID: 29635214
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.
Bogusz J; Zrubek K; Rembacz KP; Grudnik P; Golik P; Romanowska M; Wladyka B; Dubin G
Sci Rep; 2017 Oct; 7(1):13399. PubMed ID: 29042609
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
13. Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.
Tipton AR; Nyabuto GO; Trendel JA; Mazur TM; Wilson JP; Wadi S; Justinger JS; Moore GL; Nguyen PT; Vestal DJ
Biochem Biophys Res Commun; 2016 Sep; 478(4):1617-23. PubMed ID: 27590579
[TBL] [Abstract][Full Text] [Related]
14. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
Darby RA; Unsworth A; Knapp S; Kerr ID; Callaghan R
Cancer Chemother Pharmacol; 2015 Oct; 76(4):853-64. PubMed ID: 26351135
[TBL] [Abstract][Full Text] [Related]
15. GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer.
Cheng L; Gou L; Wei T; Zhang J
Int J Oncol; 2020 Sep; 57(3):858-870. PubMed ID: 32582960
[TBL] [Abstract][Full Text] [Related]
16. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
Holder SL; Abdulkadir SA
Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
[TBL] [Abstract][Full Text] [Related]
17. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode.
Lee SJ; Han BG; Cho JW; Choi JS; Lee J; Song HJ; Koh JS; Lee BI
PLoS One; 2013; 8(7):e70358. PubMed ID: 23936194
[TBL] [Abstract][Full Text] [Related]
19. New pyrazolopyrimidine derivatives with anticancer activity: Design, synthesis, PIM-1 inhibition, molecular docking study and molecular dynamics.
Philoppes JN; Khedr MA; Hassan MHA; Kamel G; Lamie PF
Bioorg Chem; 2020 Jul; 100():103944. PubMed ID: 32450389
[TBL] [Abstract][Full Text] [Related]
20. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
